CAS 1118567-05-7

Bexagliflozin

CAS: 1118567-05-7

(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Fórmula: C₂₄H₂₉ClO₇

Pureza: 98%

Peso molecular: 464.94

Ref: IN-DG629906

EGT1442

CAS: 1118567-05-7

Fórmula: C₂₄H₂₉ClO₇

Pureza: 99%

Forma y color: Solid

Peso molecular: 464.9359

Ref: IN-DA008TOL

Bexagliflozin

CAS: 1118567-05-7

Bexagliflozin

Fórmula: C₂₄H₂₉ClO₇

Pureza: ≥98%

Peso molecular: 464.94

Ref: 54-BUP03804

Bexagliflozin

CAS: 1118567-05-7

Fórmula: C₂₄H₂₉ClO₇

Peso molecular: 464.94

Ref: 4Z-B-295001

Bexagliflozin

CAS: 1118567-05-7

Bexagliflozin (EGT1442) is a potent, selective sodium glucose co-transporter 2 (SGLT2) inhibitor with IC50 values of 2 nM for human SGLT2.

Fórmula: C₂₄H₂₉ClO₇

Pureza: 98.99% - 99.89%

Forma y color: Solid

Peso molecular: 464.94

Ref: TM-T7217

Bexagliflozin

Producto controlado

CAS: 1118567-05-7

Fórmula: C₂₄H₂₉ClO₇

Forma y color: Neat

Peso molecular: 464.94

Ref: TR-B336785

Bexagliflozin

CAS: 1118567-05-7

Bexagliflozin is a drug that is used to treat type II diabetes in adults. It helps to control blood sugar levels by inhibiting the enzyme DPP-IV and increasing insulin release from the pancreas. Bexagliflozin has been shown to be effective in lowering blood sugar levels in patients with chronic kidney disease and cancer, as well as those with a body mass index (BMI) of 30 or higher. This drug is an oral hypoglycaemic agent that can be used for diagnostic purposes. It has also been shown to be clinically effective for the treatment of diabetic nephropathy and diabetic retinopathy. The enantiomers of bexagliflozin can be differentiated according to their pharmacological properties, which may allow for more targeted therapy.

Fórmula: C₂₄H₂₉ClO₇

Pureza: Min. 95%

Peso molecular: 464.94 g/mol

Ref: 3D-FA145137

Bexagliflozin

CAS: 1118567-05-7

Fórmula: C₂₄H₂₉ClO₇

Peso molecular: 464.94

Ref: ST-EA-CP-B168000